↓ Skip to main content

Dove Medical Press

Article Metrics

Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study

Overview of attention for article published in Neuropsychiatric Disease and Treatment, April 2018
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
9 Mendeley
Title
Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study
Published in
Neuropsychiatric Disease and Treatment, April 2018
DOI 10.2147/ndt.s152252
Pubmed ID
Authors

Subsai Kongsaengdao, Narong Maneeton, Benchalak Maneeton

Abstract

The short-term quality of life (QoL) in cervical dystonia (CD) after treating with abobotulinum toxin A (Abo-BTX A) and neubotulinum toxin A (Neu-BTX A) have been studied in Thai CD patients. However; the long-term study has not been published. The aim of the present study was to determine long-term improvement of the health-related quality of life (HRQoL) after eight injections of Abo-BTX A over 2 years in CD patients. A 2-year prospective study on the QoL of CD patients, as measured by HRQoL, before and after receiving eight injections of Abo-BTX A at 3-month intervals over a 2-year treatment period was performed. The disease-specific HRQoL was assessed before and after the treatment by using the Cervical Dystonia Impact Profile-58 (CDIP-58) questionnaire. The general HRQoL was assessed by using the Medical Outcomes 36-Item Short Form Health Survey (SF-36), while depressive disorder screening was assessed by using the Center of Epidemiologic Studies-Depression (CES-D) questionnaire. The SF-36 and CES-D questionnaire were administered before treatment and every 3 months before the next injection for a 2-year period. A total of 20 CD patients were enrolled from January 2013 to December 2015. CDIP-58 showed a significant improvement after long-term injections of Abo-BTX A in all domains (P < 0.001). However, only vitality domain of SF-36, which assessed general HRQoL, showed a significant improvement after long-term injections (P = 0.037). There was no prevalence of depressive disorder in all patients (CES-D score <20) in this study. The Abo-BTX A injections at 3-month intervals over a 2-year period improved the CDIP-58 scores, which assess disease-specific HRQoL, as well as an increased vitality domain of general HRQoL. No patient suffered from depression in this study.

Mendeley readers

The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 9 100%

Demographic breakdown

Readers by professional status Count As %
Other 3 33%
Student > Bachelor 1 11%
Student > Postgraduate 1 11%
Student > Ph. D. Student 1 11%
Unknown 3 33%
Readers by discipline Count As %
Medicine and Dentistry 2 22%
Neuroscience 1 11%
Agricultural and Biological Sciences 1 11%
Unknown 5 56%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 April 2018.
All research outputs
#12,950,186
of 14,687,610 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,968
of 2,442 outputs
Outputs of similar age
#237,626
of 275,081 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#55
of 78 outputs
Altmetric has tracked 14,687,610 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,442 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,081 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 78 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.